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Abstract
Background/Objectives—Maternal obesity increases risk for childhood obesity, but molecular 
mechanisms are not well understood. We hypothesized that primary umbilical vein endothelial 
cells (HUVEC) from infants of overweight and obese mothers would harbor transcriptional 
patterns reflecting offspring obesity risk.
Subjects/Methods—In this observational cohort study, we recruited 13 lean (pre-pregnancy 
BMI <25.0 kg/m2) and 24 overweight-obese (‘ov-ob’, BMI ≥25.0 kg/m2) women. We isolated 
primary HUVEC, and analyzed both gene expression (Primeview, Affymetrix) and cord blood 
levels of hormones and adipokines.
Results—142 transcripts were differentially expressed in HUVEC from infants of overweight-
obese mothers (false discovery rate, FDR <0.05). Pathway analysis revealed that genes involved in 
mitochondrial and lipid metabolism were negatively correlated with maternal BMI (FDR <0.05). 
To test whether these transcriptomic patterns were associated with distinct nutrient exposures in 
the setting of maternal obesity, we analyzed the cord blood lipidome and noted significant 
increases in levels of total free fatty acids (lean: 95.5 ± 37.1 ug/ml, ov-ob: 124.1 ± 46.0 ug/ml, 
P=0.049), palmitate (lean: 34.5 ± 12.7 ug/ml, ov-ob: 46.3 ± 18.4 ug/ml, P=0.03) and stearate (lean: 
20.8 ± 8.2 ug/ml, ov-ob: 29.7 ± 17.2 ug/ml, P=0.04), in infants of overweight-obese mothers.
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Conclusion—Prenatal exposure to maternal obesity alters HUVEC expression of genes involved 
in mitochondrial and lipid metabolism, potentially reflecting developmentally-programmed 
differences in oxidative and lipid metabolism.
Introduction
Evidence from human populations and animal models indicates that environmental 
exposures during early development are critical determinants of disease susceptibility 
throughout the lifespan, a phenomenon termed ‘developmental programming’ (1). A wide 
range of prenatal perturbations, including maternal undernutrition, obesity, diabetes, high-fat 
diet, and endocrine-disrupting chemicals, are now recognized as risk factors for chronic 
diseases including diabetes, obesity, and cardiovascular disease (2–4). Maternal obesity is of 
particular concern, as it is a potent risk factor for childhood obesity: offspring of mothers 
entering pregnancy with BMI >30 kg/m2 have a 1.5 to 4-fold higher risk of childhood 
obesity (5). Studies of siblings born before vs. after a mother’s weight loss surgery - which 
minimize the contribution of shared genetics - suggest that in utero exposure to maternal 
obesity per se can increase risk of childhood obesity >2-fold (6, 7).
Unfortunately, the molecular mechanisms by which maternal obesity increases metabolic 
risk in offspring remain incompletely understood. Previous rodent and primate studies 
indicate that maternal insulin resistance, which is tightly correlated with maternal obesity 
(8), may be one contributor to obesity-associated developmental programming (9, 10). Other 
mediators may include shared environmental risk factors, epigenetics, and/or hormonal and 
metabolic adaptations to an ‘obese’ intrauterine environment. Fewer mechanistic studies 
have examined metabolic phenotypes in humans, largely due to the practical and ethical 
challenges of obtaining cells and tissues from infants. However, umbilical cords, which are 
usually discarded after delivery, provide an accessible source of infant cells for translational 
studies. Interestingly, analysis of umbilical cord segments from infants of women with type 
1 diabetes identified differences in expression of genes related to vascular development and 
function (11).
Primary human umbilical vein endothelial cells (HUVEC) are readily isolated, remain viable 
and metabolically active in culture, and are insulin-responsive, features leading to their wide 
use in vascular biology for over 40 years (12), and more recently, in studies of fetal 
adaptations to maternal diabetes and placental insufficiency. For example, maternal 
gestational diabetes is associated with reduced vasodilation (13) and increased leukocyte 
adhesion in HUVEC (14), potentially mediated by specific miRNAs (15). Moreover, 
increased eNos promoter methylation has been reported in HUVEC from infants with 
intrauterine growth restriction (IUGR) (16).
We therefore hypothesized that maternal obesity would alter metabolism in HUVEC in a 
cell-autonomous fashion. We now demonstrate that maternal obesity is associated with a 
dramatic transcriptional response in infant HUVEC, particularly within pathways related to 
lipid metabolism and mitochondrial structure/function, and is accompanied by increases in 
cord blood insulin, palmitate, and stearate.
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Methods
Human subjects - Recife Cohort
Pregnant women were recruited during prenatal visits at Instituto de Medicina Integral Prof. 
Fernando Figueira, Recife, Brazil. Eligibility criteria included: age ≥18 years and known 
gestational age (based on date of last menstrual period (LMP) or ultrasound before 16 
weeks). Exclusion criteria included: diabetes diagnosed prior to or during the current 
pregnancy, multiple gestation, hypertension, artificial reproductive techniques, HIV, syphilis, 
maternal disease requiring medications known to affect fetal growth or glucose metabolism, 
fetal congenital malformations, premature delivery (<36 weeks), and deliveries occurring 
outside the study hospital. Participants were grouped by early pregnancy BMI, defined as 
BMI at the first prenatal visit (<12 weeks gestation): lean (<25.0 kg/m2) vs. overweight and 
obese (‘ov-ob’, ≥25.0 kg/m2). The study protocol was approved by the Hospital Institutional 
Review Board and the National Committee for Ethics in Research at National Health 
Council (CONEP-Statement # 387/2011), Brasilia, Brazil, and by the Committee for Human 
Subjects at Joslin Diabetes Center, Boston, Massachusetts. All participants provided written 
informed consent.
Assessments during pregnancy – Recife Cohort
At the first prenatal visit, maternal medical history, including systemic disease, smoking, 
obstetric history, and clinical data (height, weight, blood pressure, date of LMP, and fasting 
glucose values) were collected. Maternal glucose metabolism was assessed twice: a 1-hour 
75 g oral glucose screen during the second trimester (24 weeks ± 2 weeks), and a 2-hour 75 
g oral glucose tolerance test (OGTT) during the third trimester (glucose and insulin at time 0 
(fasting), 1, and 2 hours (30 weeks ± 2 weeks). Homeostasis method assessment of insulin 
resistance (HOMA-IR) was calculated as [(Glucose × Insulin) / 405], and homeostatic 
method assessment of beta cell secretion (HOMA-β) as [(360 × Insulin)/(Glucose − 63)], as 
described (17). Fasting cholesterol, HDL, LDL, VLDL, and triglycerides were also assessed 
during the third trimester GTT visit. The final maternal BMI was calculated during the last 
prenatal visit (36 – 40 weeks). Cord blood was collected at delivery and plasma aliquots 
frozen. Newborn weight, length, head circumference, and abdominal girth were measured 
within the first 24 hours of life by trained nurses. Newborn weight for gestational age and 
sex percentiles were derived from the growth curves of Olsen et al.(18); small for gestational 
age was defined as birth weight < 10th percentile, while large for gestational age was defined 
as birth weight >90th percentile. Medical records were abstracted to obtain data regarding 
prenatal, labor and delivery, postpartum, and neonatal course.
Laboratory analysis
Plasma glucose, hemoglobin A1c, and lipids were analyzed using a colorimetric method 
(Architect c8000, Abbott); LDL cholesterol was calculated using the Friedwald formula. 
Insulin was measured using an electrochemiluminescence immunoassay (Siemens). 
Urinalysis, HIV, and syphilis tests were performed using Symex XT-1800 (Roche), and 
URiSCAN Pro II, YD, AxSYM System (Abbott) and ELISA immunoassay (Elisys Quattro) 
respectively. Cord blood IL-1β, IL-6, IL-8, leptin, adiponectin, resistin, total PAI-1, MCP-1, 
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HGF and TNF-α levels were determined by multiplex ELISA (Milliplex) in the Joslin DRC 
Specialized Assay Core.
HUVEC isolation
Umbilical cord segments (10 cm) were transported to the lab within 1 hour of delivery, and 
kept on ice in buffer containing PBS and antibiotics until HUVEC isolation; all isolations 
were performed within 2h of delivery. Umbilical segments were rinsed with PBS, and the 
umbilical vein was cannulated using a 3-way stopcock (Poly Medicure Limited (India), 
MODEL #1021). The umbilical vein was rinsed twice with 50 ml PBS before infusion with 
25 ml 0.1% collagenase (Gibco, Cat. No.# 17100-017) dissolved in 37°C PBS. The cord was 
clamped at both ends and incubated at room temperature for 30 minutes. The cord was then 
unclamped and the vein flushed with vascular cell complete growth media (ATCC, 
PCS-100-030, containing 100 mg/dl glucose), and the effluent collected. The cells were then 
centrifuged and resuspended in complete growth media. Vascular cell growth media contains 
VEGF (5 ng/mL), EGF (5 ng/mL), FGF basic (5 ng/mL), IGF-1 (15 ng/mL), L-glutamine 
(10 mM), heparin sulfate (0.75 Units/mL), hydrocortisone (1 µg/mL), ascorbic acid (50 
µg/mL) and fetal bovine serum (2%) (ATCC Endothelial Cell Growth Kit, PCS-100-041).
RNA isolation and microarray analysis
For each cell line, an aliquot of freshly isolated HUVEC was stored in RNA Later reagent 
(Life Technologies) at −80°C until RNA extraction, using Trizol (Life Technologies) 
according to the manufacturer’s protocol, with glycogen (AM9510, Life Technologies) 
added as a carrier. cRNA was prepared and hybridized to Affymetrix PrimeView 
microarrays. Data were normalized using Robust Multichip Average (RMA) (19) and log-2 
transformed. Normalized microarray data were analyzed (p, FDR) using GenePattern 
Comparative Marker Selection module (Broad Institute). Heatmaps were created using 
GENE-E (Broad Institute). Pathway analyses were performed using Gene Set Enrichment 
Analysis (GSEA, Broad Institute) (20, 21) and DAVID (Bioinformatics Resources v6.7) 
(22).
Quantitative RT-PCR
Complementary DNA (cDNA) was generated using High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies) with 500 ng input RNA. Expression of selected genes 
was assessed by qRT-PCR, with expression normalized to cyclophilin E (PPIE), using an 
ABI 7900 HT thermocycler. Primer sequences are available upon request.
Lipidomic analysis
Lipidomic analyses in cord plasma samples were performed at the Vanderbilt Lipid Core. 
Lipids were extracted (23), filtered, and recovered in the chloroform phase prior to 
separation by thin layer chromatography. Phospholipids, diacylglycerides, triglycerides and 
cholesteryl esters were scraped from the plates and methylated (24); methylated fatty acids 
were extracted and analyzed by gas chromatography (Agilent 7890A) with helium, and 
compared to known standards (C15:0, C17:0, C20:1, and cholesteryl eicosenoate (C20:1)). 
For total cholesterol, an internal standard (5-alpha-cholestane) was added to a portion of the 
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lipid extract and saponified at 80 C in 1 N KOH in 90% methanol for 1 hour. The non-
saponifiable sterol was extracted into hexane, concentrated under nitrogen, and solubilized 
in carbon disulfide to inject onto the gas chromatograph. For unesterified cholesterol, an 
internal standard is added to the lipid extract, concentrated under nitrogen and solubilized in 
carbon disulfide to inject onto the gas chromatograph (25). We calculated the ratio of 
palmitoleate (16:1n7) to palmitate (16:0), and of oleic acid (18:1n9) to oleate (18:0) as a 
readout of delta-9 desaturase activity, as described (26).
Statistical analysis
Data are reported as mean ± standard deviation. Between-group comparisons were 
performed by unpaired, unequal variance, two-sided T-tests for continuous data, and Fisher’s 
exact test for categorical data (JMP 10, SAS Corporation, Cary, NC). To adjust for multiple 
comparisons, false discovery rates were calculated using R software.
Results
Clinical, metabolic, and hormonal characteristics of mothers and newborns
Maternal age tended to be higher in the overweight/obese (‘ov-ob’) group (lean: 24.6 ± 5.4, 
ov-ob: 27.9 ± 5.9 years, P=0.1, Table 1). As expected, women in the ov-ob group had 
significantly higher first trimester BMI than lean women (lean: 21.9 ± 1.7 vs. ov-ob: 32.2 
± 5.7 kg/m2, P<0.0001), and higher BMI at the last prenatal visit (lean: 27.6 ± 3.4 vs. ov-ob: 
36.2 ± 6.6 kg/m2, P<0.0001). Gestational weight gain was lower in the ov-ob group (lean: 
11.5 ± 4.5 vs. ov-ob: 7.8 ± 4.5 kg, P=0.03), but the proportion of women with excessive 
gestational weight gain (2009 IOM criteria) (27) was numerically higher in ov-ob (lean: 1/13 
or 7.7%, ov-ob: 6/24 or 25%, P=0.38). Diastolic blood pressure was higher in the ov-ob 
group (lean: 62 ± 7 mmHg, ov-ob: 69 ± 10 mmHg, P=0.02), but systolic blood pressure was 
unaltered. While fasting glucose did not differ at 24 or 30 weeks, blood glucose 1 hour after 
glucose challenge at 24 weeks tended to be higher in ov-ob (lean: 105.0 ± 26.8 vs. ov-ob: 
126.4 ± 32.6 mg/dl, P=0.09), as was 2 hour glucose at 30 weeks (lean: 117.4 ± 14.2, ov-ob: 
134.9 ± 28.2 mg/dl, P=0.02). Insulin resistance (HOMA-IR), insulin secretion index 
(HOMA-β) and insulin levels during OGTT were similar, as were lipid levels.
Gestational age at delivery, birth weight, and newborn adiposity measures, including 
ponderal index and abdominal circumference, were similar between offspring of lean vs. ov-
ob mothers (Table 2). Cord blood insulin was increased 2-fold in ov-ob (lean: 4.6 ± 3.9, ov-
ob: 9.0 ± 9.1 µU/mL, P=0.048), as were leptin levels (lean: 23.9 ± 19.4, ov-ob: 48.9 ± 43.6 
µg/mL, P=0.02). Other hormones and adipokines in cord blood approached statistical 
significance, notably hepatocyte growth factor (HGF), IL-6, and TNF-α, which tended to be 
higher, and PAI-1, which tended to be lower, in infants of ov-ob mothers.
Maternal obesity alters gene expression patterns in HUVEC
To test whether prenatal exposure to maternal obesity alters transcriptional patterns in infant 
cells, we analyzed global gene expression in a randomly selected subset of primary HUVEC 
(PrimeView microarray, Affymetrix). Characteristics of mothers and newborns included in 
the microarray analysis tended to be similar to the entire cohort, although cord blood levels 
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of HGF, resistin, and TNF-α were more significantly increased in the array subset 
(Supplemental Table 1). Principal components analysis showed only modest separation of 
lean vs. ov-ob infants based on gene expression, with substantial overlap between groups 
(Supplemental Figure 1). 4916 transcripts were altered by maternal obesity (P<0.05), with 
142 remaining different after adjustment for multiple comparisons (FDR<0.05), all of which 
were upregulated in ov-ob (complete list in Supplemental Table 2 A). As seen in the volcano 
plot in Figure 1A, more transcripts were upregulated by maternal obesity than 
downregulated. Strikingly, many of the top-ranking differentially expressed genes were 
related to lipid metabolism (e.g. LPIN2, MGAT2, DGAT1, SREBP2), insulin signaling (e.g. 
MAP4K5, PIK3R1, PRKACB, MAP3K13) and mitochondrial metabolism (e.g. COX18, 
ATP5D) (Figure 1B). Similarly, several genes related to lipid metabolism (e.g. LDLR, 
ANGPTL4, LMNA) (28, 29) were top-ranking in terms of fold-change (increased in Ov-Ob, 
Supplemental Table 2C–D). We next examined correlations between maternal BMI and gene 
expression, and found that several mitochondrial genes (e.g. ATP5O, ATP5C1, COX7C, 
NDUFB6, TMEM14C) were inversely correlated with maternal BMI, whereas the lipid 
metabolism genes FADS2 and FADS3, insulin-like growth factor 1 receptor (IGF1R) and 
receptor tyrosine-protein kinase erbB-2 (ERBB2) where strongly positively correlated with 
maternal BMI (Figure 1C). qRT-PCR confirmed significant upregulation of LDL receptor 
(LDLR), UDP-glucose ceramide glucosyltransferase (UGCG), erb-b2 receptor tyrosine 
kinase 2 (ERBB2), G protein pathway suppressor 1 (GPS1), Kruppel-like factor 7, and 
TNFAIP3 interacting protein 2 (TNIP2) in HUVEC from infants exposed to maternal 
obesity, consistent with microarray patterns. We also confirmed a significant, positive 
correlation between maternal BMI and PRKAB1 (Figure 2A/D).
Mitochondrial and lipid metabolism transcriptional pathways are altered by maternal 
obesity
We next performed Gene Set Enrichment Analysis (GSEA) to analyze enrichment of Gene 
Ontology (GO) terms in genes correlating with maternal BMI. 98 GO terms were positively 
correlated with BMI (q<0.05), including pathways related to ion channels, transmembrane 
transporters, and neurotransmitter activity. 73 GO terms were inversely correlated (q<0.05). 
The top-ranking set inversely correlated with maternal BMI was “proton-transporting two 
sector ATPase complex”; many other inversely correlated pathways were related to 
mitochondria (e.g. mitochondrial small ribosomal subunit, matrix, aerobic respiration) and to 
lipid metabolism (e.g. fatty acid biosynthesis, beta-oxidation, lipid catabolism). Pathway 
analyses are shown in Supp Tables 3A/B.
Maternal obesity associated with reduced maternal LDL cholesterol and increased fatty 
acid and triglyceride species in cord blood
We next asked whether altered HUVEC gene expression, particularly within lipid and 
mitochondrial pathways, might reflect differences in nutrient exposure. Maternal LDL 
cholesterol tended to be lower in ov-ob mothers (lean: 146±28, ov-ob: 121±40 mg/dl, 
P=0.06), but levels of triglycerides and HDL were similar. In infant cord blood, there was a 
trend for increased levels of several triglyceride and fatty acid species from offspring of ov-
ob mothers (Figure 4A). Notably, levels of total free fatty acids, and of two saturated fatty 
acids, palmitate (16:0) and stearate (18:0), were significantly increased (1.3, 1.3 and 1.4-
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fold, respectively, P<0.05, Figure 4B/C). Moreover, several triglyceride species containing 
long-chain and omega-6 fatty acids were increased by 1.5 to 2.3-fold in the ov-ob group 
(TAG18:3w6, TAG20:4, TAG22:4w6, and TAG22:5w6, P<0.05) (Figure 4C). The ratio of 
TAG18:1n9 to TAG18:0, a surrogate for desaturase activity, was significantly higher in ov-
ob, suggesting increased SCD-mediated lipogenesis (Figure 4E). Interestingly, cholesterol 
esters and phospholipids containing the rare essential fatty acid 20:3w6 (dihomo-gamma-
linolenic acid, DGLA) were negatively correlated with pre-pregnancy BMI (CE20:3w6: 
Pearson r= −0.45, P=0.005; PL20:3w6: r= −0.37, P=0.02, Figure 4D). Since levels of DGLA 
may be influenced by activity of delta-5 and delta-6 desaturase enzymes, it is interesting that 
expression of FADS2 (delta-6 desaturase) and FADS3 (delta-5 desaturase) were positively 
correlated with maternal BMI (Supplemental Figure 2). Strikingly, we noted strong 
correlations between levels of cord blood CE20:3w6 and expression of several transcripts 
related to lipid metabolism, including monoglycerate lipase (MGLL) and SREBP2, and the 
mitochondrial gene ATP5D (Supplemental Figure 3A). Cord blood palmitate (16:0) and 
stearate (18:0) also correlated with expression of PPARG2 (Supplemental Figure 3B) and 
several other transcripts dysregulated in ov-ob (e.g. correlation of 16:0 vs. NDUFB6 R=
−0.62, P=0.02; KLF7, R=0.615, P=0.02; ARID4B, R=0.73, P=0.003). Together, these data 
raise the possibility that altered plasma lipid species might contribute to differential gene 
expression in HUVEC from infants of overweight-obese mothers.
Discussion
Given that HUVEC are exclusively fetal in origin, they provide a powerful model to test 
whether prenatal exposures such as maternal obesity result in cell autonomous 
transcriptional patterns in offspring. In this study, we perform the first analysis of 
transcriptional responses to maternal obesity in HUVEC. Strikingly, maternal obesity was 
associated with marked perturbations in gene expression in offspring HUVEC, with 
downregulation of numerous genes related to mitochondrial function and lipid metabolism. 
Transcriptional patterns in infant HUVEC were closely correlated with cord blood levels of 
the fatty acids palmitate and stearate, and with lipids containing 20:3w6, raising the 
possibility that plasma lipids may mediate altered gene expression patterns in HUVEC. 
Whether such transcriptional patterns might result from direct nutrient exposures, or indirect 
epigenetic mechanisms, will be a key question for future studies. Furthermore, it will be 
important to determine whether these expression patterns can serve as markers or mediators 
of metabolic disease risk in infants of overweight/obese mothers.
Many of the differentially expressed genes identified in our analysis have previously been 
linked to obesity, diabetes, or other metabolic traits. For example, decreased adipose 
expression of SREBP2 and other genes involved in lipolysis and triglyceride synthesis, has 
been reported in adipose tissue from women with GDM and/or obesity (30). Expression of 
the cholesterol regulatory gene LDLR (31), was increased in HUVEC of ov-ob mothers. For 
several other top-ranking genes identified in our analysis (e.g. LPIN2, KLF7, PPARG2), 
SNPs within these loci have been linked to obesity and type 2 diabetes risk (32–34). 
Intriguingly, ERBB2, which was upregulated in infants of ov-ob mothers, has previously 
been linked to maternal obesity; differences in methylation of ERBB2 in cord blood 
leukocytes have been linked to pre-pregnancy maternal BMI (35). It will thus be important 
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for future studies to examine whether differences in infant expression of ERBB2 and other 
genes identified in our analysis, may be associated with differences in DNA methylation or 
other forms of epigenetic regulation.
Another striking pattern in HUVEC from infants exposed to maternal obesity is altered 
expression of individual genes and transcriptional pathways related to mitochondrial 
metabolism. A large body of evidence has linked diabetes and obesity to reduced adipose, 
muscle, and liver expression of genes involved in mitochondrial oxidation (21, 36). 
Moreover, functional defects in mitochondrial oxidation have been reported in humans with 
diabetes and obesity, and in rodent models of adverse prenatal exposures (37). In mice, 
maternal high fat diet reduces oocyte mitochondrial number and function (38). However, 
evidence from human infants is much more limited. Maternal obesity has been associated 
with reduced mitochondrial function in human placenta (39, 40), but given that the placenta 
contains maternal and fetal cells in close proximity, dissecting the cause of such 
transcriptional patterns is challenging. Our data in HUVEC, cells of purely fetal origin, 
suggest that altered mitochondrial gene expression may be an early marker of infant 
metabolic disease risk resulting from maternal obesity. Transcriptional patterns in HUVEC 
from infants of Ov-Ob mothers, moreover, appear distinct from previous analyses of 
HUVEC from infants of mothers with GDM (41), which highlighted differences in gene 
pathways related to extracellular matrix remodeling and insulin binding proteins. Gene 
expression patterns in the Ov-Ob group were somewhat more similar to a published analysis 
of transcriptional patterns in HUVEC exposed to acute insulin treatment, which identified 
“Electron Transport Chain” as a top-ranking significantly altered pathway (42).
In our analysis of individual genes altered by maternal obesity, we found that several genes 
critical for insulin signaling, including PIK3R1, MAP4K5, and MAP3K13, ranked among 
the most significantly differentially regulated transcripts. These data are intriguing in light of 
the recent study by Thakali et al. reporting increased phosphorylation of AKT, an insulin 
signaling node downstream of PI3-kinase, in umbilical cord segments from infants of 
overweight/obese mothers (43), and several reports of impaired PI3 kinase activation in 
rodent models of developmental programming (44–46). Together, these data raise the 
possibility that the PI3-kinase pathway may be susceptible to modulation by prenatal 
perturbations.
To test whether nutrient exposures might mediate transcriptional responses to maternal 
obesity in infant HUVEC, we analyzed the cord blood lipidome. Total free fatty acids, as 
well as individual lipids including palmitate (16:0), stearate (18:0), and triglycerides 
containing 18:3w6, 22:4w6, 22:5w6 and 20:4, were significantly increased in cord blood 
from infants of ov-ob women. Moreover, the ratio of 18:1n9 to 18:0, a surrogate for SCD1 
delta-9 desaturase activity, was increased in the ov-ob group, similar to patterns in infants of 
women with gestational diabetes (47). By contrast, lipid species containing 20:3w6 fatty 
acids (e.g. CE20:3w6, PL20:3w6) were negatively correlated with maternal BMI. Previous 
reports have documented increases in plasma 20:3w6 (di-homo gamma linolenic acid, 
DGLA), and in phospholipids containing DGLA, in obese humans (reviewed in (48)). 
Moreover, maternal plasma levels of (20:3w6, or DGLA) during pregnancy have been 
associated with childhood obesity risk at age 7 years (49). By contrast, dietary DGLA 
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supplementation in mice may protect against atherosclerosis (50). These data raise the 
intriguing possibility that reductions in plasma DGLA in infants of obese women might 
contribute to increased atherosclerosis risk. More broadly, the observation that 
transcriptional pathways involved in lipid metabolism, together with cord blood lipid levels, 
are altered by maternal obesity may have relevance to offspring vascular function given the 
recent discovery that fatty acid oxidation by endothelial cells is critical for proliferative 
capacity (51). Surprisingly, we did not observe any differences in plasma triglycerides in ov-
ob vs. lean women, which stands in contrast to previous studies demonstrating associations 
between maternal BMI and serum triglycerides (52). It is difficult to assess whether the lack 
of association is due to the genetics, environment, or diet of this Brazilian group of women, 
as we unfortunately do not have information about these characteristics. This will be an 
important area for future studies, as maternal triglyceridemia may be an important 
contributor to fetal macrosomia, a key risk factor for future metabolic disease in offspring 
(53).
We acknowledge that our study has several limitations. First, our sample size is small, which 
limits our power to detect differences, and may limit the generalizability of our findings. Our 
limited sample size, moreover, prevented us from adjusting for offspring sex, mode of 
delivery, maternal age, and other covariates that might influence infant weight status or 
metabolism. Secondly, the infants were not observed beyond the newborn period, so we 
cannot assess whether the transcriptional patterns observed in HUVEC, or the hormonal/
lipidomic differences in cord blood, were linked to the development of obesity or other 
metabolic diseases in offspring. Thirdly, we did not exclude infants with fetal growth 
restriction (SGA) or growth excess (LGA), so we cannot exclude the possibility that infant 
weight status, rather than maternal obesity, might drive the phenotypes we observed. Finally, 
we recognize that analyses of transcriptomic and metabolic variables in humans cannot 
prove causality. Nevertheless, as a readily isolated cell of purely fetal origin, HUVEC 
provide evidence for how prenatal perturbations such as maternal obesity may alter cellular 
responses in offspring. HUVEC provide a robust model for testing how maternal obesity 
may alter lipid metabolism, insulin signaling, nutrient sensing or other key cellular pathways 
in infants.
In summary, we tested whether prenatal exposure to maternal obesity influences 
transcriptional responses in infant cells. We found that maternal obesity alters expression of 
genes related to mitochondrial and lipid metabolism. Transcriptional patterns were 
associated with altered levels of cord blood lipids, notably palmitate, stearate, and lipids 
containing omega-6 fatty acids. These data suggest that altered lipid metabolism may be an 
early signature of mother-to-child transmission of obesity and metabolic disease risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Global gene expression patterns in HUVEC isolated from infants of overweight-obese 
mothers vs. controls
A. Volcano plot.
B. Heatmap – top 200 differentially regulated probes, selected based on Comparative Marker 
Selection scores, GenePattern, Broad Institute.
C. Heatmap of top-ranking probesets correlating with maternal BMI, selected based on 
Pearson’s R≥0.75 and R≤0.75. The full gene list is available in Supplemental Table 2B.
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Figure 2. Validation of HUVEC gene expression patterns identified by array data using Q-PCR
A. Array expression of top-ranking differentially expressed genes in HUVEC from infants of 
Ov-Ob vs. lean mothers, including erb-b2 receptor tyrosine kinase 2 (ERBB2), G protein 
pathway suppressor 1 (GPS1), Kruppel-like factor 7 (KLF7), low density lipoprotein 
receptor (LDLR), TNFAIP3 interacting protein 2 (TNIP2), and UDP-glucose ceramide 
glucosyltransferase (UGCG). N=14.
B. qRT-PCR expression of ERBB2, GPS1, KLF7, LDLR, TNIP2, and UGCG, normalized to 
PPIE and to expression in lean controls. N=20.
C. Based on array analysis, HUVEC expression of protein kinase, AMP-activated, beta 1 
non-catalytic subunit (PRKAB1) is positively correlated with maternal pre-pregnancy BMI. 
N=14.
D. qRT-PCR expression of PRKAB1, normalized to PPIE, is positively correlated with 
maternal pre-pregnancy BMI. N=20. * P<0.05, ** P<0.01, ***P<0.0001.
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Figure 3. Maternal obesity alters infant cord blood lipidome
A. Overview of lipid composition of cord blood. Each column represents a class of lipids, 
and each row represents a fatty acid comprised within the lipid class. Each lipid subset was 
quantified by LC/MS; then normalized to the level in infants of lean mothers. Data are 
expressed as fold-change in ov-ob/lean. FFA: Free fatty acids; DAG: diacylglycerides; TAG: 
triacylglycerides; CE: cholesterol esters; PL: phospholipids.
B. Cord blood total fatty acids (ug/ml). N=37.
C. Cord blood FFA16:0, FFA18:0, omega-6 conjugated triglycerides and TAG20:4 are 
increased in infants of overweight/obese women. All lipid levels expressed as µg/ml. N=37.
D. 20:3w6-conjugated cholesterol esters and phospholipids are inversely correlated with 
maternal BMI. N=37.
E. The ratio of 18:1n9 to 18:0 triglycerides, a surrogate for stearoyl-coA desaturase 1 
(SCD1) activity, is increased in cord blood from infants of Ov-Ob women. N=37.
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Table 1
Maternal pregnancy characteristics according to early pregnancy weight category.
Maternal Data BMI < 25.0 kg/m2 BMI ≥ 25.0 kg/m2 P-value
Age (years) 24.6 ± 5.4 (13) 27.9 ± 5.9 (24) 0.1
Early BMI 21.9 ± 1.7 (13) 32.2 ± 5.7 (24) <0.0001
Final BMI 27.6 ± 3.4 (13) 36.2 ± 6.6 (24) <0.0001
Weight Gain (kg) 11.5 ± 4.5 (13) 7.8 ± 4.5(24) 0.03
Height (meters) 1.60 ± 0.06 (13) 1.59 ± 0.07 (24) 0.56
Systolic BP (mm Hg) 105 ± 15 (13) 109 ± 13 (24) 0.41
Diastolic BP (mm Hg) 62 ± 7 (13) 69 ± 10 (24) 0.02
Hematocrit (%) 36.3 ± 2.7 (13) 36.4 ± 3.5 (24) 0.98
Hemoglobin (g/dl) 11.8 ± 1.0 (13) 12.1 ± 1.3 (24) 0.49
Fasting Glucose 1st trimester (mg/dl) 78.6 ± 8.4 (11) 79.9 ± 7.2 (24) 0.64
Glucose 1h OGTT 24 weeks (mg/dl) 105.0 ± 26.8 (9) 126.4 ± 32.6 (22) 0.09
Fasting Glucose OGTT 30weeks (mg/dl) 75.7 ± 5.4 (12) 78.0 ± 10.2 (22) 0.40
Glucose 1h OGTT 30 weeks (mg/dl) 134.9 ± 18.9 (12) 139.0 ± 24.0 (22) 0.61
Glucose 2h OGTT 30 weeks (mg/dl) 117.4 ± 14.2 (12) 134.9 ± 28.2 (22) 0.02
Fasting Insulin OGTT 30 weeks (uU/ml) 9.9 ± 3.5 (11) 12.4 ± 7.0 (22) 0.27
Insulin 1h OGTT 30 weeks (uU/ml) 106.9 ± 52.3 (11) 112.3 ± 70.3 (21) 0.82
Insulin 2h OGTT 30 weeks (uU/ml) 106.4 ± 64.2 (11) 126.8 ± 83.4 (22) 0.48
HOMA-IR 1.9 ± 0.7 (11) 2.5 ± 1.6 (22) 0.24
HOMA-B (%) 478 ± 640 (11) 432 ± 347 (22) 0.79
Total Cholesterol (mg/dl) 252.7 ± 31.4 (12) 233.6 ± 41.5 (22) 0.18
HDL-Cholesterol (mg/dl) 66.0 ± 10.8 (12) 66.7 ± 16.6 (22) 0.90
LDL-Cholesterol (mg/dl) 146.2 ± 28.0(12) 121.4 ± 39.5 (22) 0.06
VLDL-Cholesterol (mg/dl) 40.6 ± 11.4 (12) 44.4 ±19.6 (22) 0.55
Triglycerides (mg/dl) 202.9 ± 56.0 (12) 200.8 ± 49.6 (22) 0.91
C-section (%) 37.1 (13) 31.6 (12) 0.49*
Mean ± SD; sample size indicated in parentheses
P-value refers to T-test, except for categorical data, where Fisher’s exact test was used (denoted by asterisk).
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Table 2
Newborn characteristics and cord blood adipokines according to maternal weight category
Newborn Data BMI < 25.0 kg/m2 BMI ≥ 25.0 kg/m2 P-value
Gestational Age (weeks) 39.1 ± 1.3 (13) 39.1 ± 1.3 (24) 0.85
Birth weight (grams) 3280 ± 662 (13) 3229 ± 508 (24) 0.81
Infant sex (M/F) 10M/3F 13M/11F 0.28
Weight for gestational age and sex
(percentile)
41.5 ± 27.1 (13) 45.2± 26.5 (24) 0.69
Head circumference (cm) 33.9 ± 1.3 (13) 34.3 ± 2.1 (24) 0.56
Abdominal girth (cm) 31.6 ± 3.0 (13) 31.6 ± 2.0 (24) 0.96
Length (cm) 48.9 ± 2.8 (13) 48.8 ± 2.7 (24) 0.93
Ponderal Index (kg/m3) 27.7 ± 2.4 (13) 27.6 ± 2.6 (24) 0.88
Cord blood hormones and
adipokines
  Insulin (µU/ml) 4.6 ± 3.9 (12) 9.0 ± 9.1 (24) 0.048
  HGF (ng/ml) 2.5 ± 1.0 (12) 3.1 ± 1.0 (24) 0.08
  Leptin (ng/ml) 23.9 ± 19.4 (13) 49.0 ± 43.6 (24) 0.02
  Adiponectin (ug/ml) 407 ± 377 (13) 337 ± 296 (24) 0.57
  Resistin (pg/ml) 174 ± 97 (12) 196 ± 110 (24) 0.55
  IL-1β (pg/ml) 0.12 ± 0.06 (12) 0.17 ± 0.29 (23) 0.50
  IL-6 (pg/ml) 11 ± 10 (12) 41.9 ± 77.7 (23) 0.07
  IL-8 (pg/ml) 61 ± 137 (12) 85 ± 210 (24) 0.68
  MCP-1 (pg/ml) 386 ± 245 (13) 314 ± 205 (23) 0.38
  TNF-α (pg/ml) 9.1 ± 2.5 (12) 10.8 ± 3.7 (24) 0.11
  Total PAI-1 (pg/ml) 186 ± 62 (13) 152 ± 32 (23) 0.08
Mean ± SD; sample size is indicated in parentheses.
P-value refers to Student’s T-test, except for Infant sex, which was analyzed by Fisher’s exact test.
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